Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain
CompletedNot applicableNCT05634291
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The aim of this run-in design, feasibility study is to assess outcomes (including opioid-use, pain intensity, emotional function, and general physical function) for an augmented reality illusion therapy in participants with chronic hand joint pain due to arthritis.
Study details
- Official title
- Effects of the Nottingham Arthritis App for Arthritis Pain
- Conditions
- Chronic Pain
- Arthritis Hand
- Opioid Use
- Interventions
- Other: Standard of care
- Device: Nottingham AR smartphone app with active intervention
- Sponsor
- VRx Medical Inc
- Collaborators
- National Institute on Drug Abuse (NIDA); San Diego Veterans Healthcare System
- Start date
- 2022-06-13
- Primary completion
- 2023-06-16
- Sex
- All
- Age range
- from 21 Years to 80 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Male and female adults ages 21-80 2. Clinical diagnosis of chronic hand pain from arthritis or as determined by study physician 3) Hand joint pain at a severity of 4 and above (on a 0 to 10 scale) daily 4\) Use of prescribed opioids 5) English-speaking, literate, with stable residence 5) Able to operate a smartphone as evidenced by direct observation. Exclusion Criteria: 1. Major medical illness that might confound effects of pain on function (e.g., advanced cardiac or pulmonary disease) 2. Current active alcohol or substance use disorder as evidenced from medical record 3. Currently active unstable psychiatric status in previous three months as measured by direct observation, patient self-report, or medical record 4. Moderate or severe cognitive impairment as demonstrated by medical diagnosis or clinical observation 5. fMRI exclusion only: Any factors that would prevent participation in fMRI
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05634291